Cargando…
Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022
This real-world study explores the effect of coronavirus disease 2019 (COVID-19) inactivated vaccines on the prevention of asymptomatic or mild Delta or Omicron variant infections progressing to pneumonia. Association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia cas...
Autores principales: | , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413898/ https://www.ncbi.nlm.nih.gov/pubmed/36016103 http://dx.doi.org/10.3390/vaccines10081215 |
_version_ | 1784775864056020992 |
---|---|
author | Li, Juan Song, Rui Yuan, Zheng Xu, Zheng Suo, Luodan Wang, Qing Li, Yuan Gao, Yanlin Li, Xiaomei Chen, Xiaoyou Wu, Jiang |
author_facet | Li, Juan Song, Rui Yuan, Zheng Xu, Zheng Suo, Luodan Wang, Qing Li, Yuan Gao, Yanlin Li, Xiaomei Chen, Xiaoyou Wu, Jiang |
author_sort | Li, Juan |
collection | PubMed |
description | This real-world study explores the effect of coronavirus disease 2019 (COVID-19) inactivated vaccines on the prevention of asymptomatic or mild Delta or Omicron variant infections progressing to pneumonia. Association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia cases and vaccination was measured with a multivariable logistic regression, stratified by genotype and age groups. We recruited 265 cases (111 (41.9%) infected with Delta and 154 (58.1%) with Omicron variants). There were 22 asymptomatic infected individuals, 156 mild cases without pneumonia, and 87 moderate cases with pneumonia. There was a markedly increased risk of progression to pneumonia in Delta infected cases, unvaccinated, or partially vaccinated COVID-19 patients with diabetes and those aged ≥60 years. Patients who had completed booster doses of inactivated vaccines had a reduced risk of 81.6% (95% CI: 55.6–92.4%) in progressing to pneumonia over those who were unvaccinated or partially vaccinated. The risk of progressing to pneumonia was less reduced by 88.7% (95% CI: 56.6–97%) and 73.9% (95% CI: 1.4–93.1%) among Delta and Omicron-infected patients, and was reduced by 78.5% (95% CI: 45.3–91.6%) and 94.1% (95% CI: 21.5–99.6%) among patients aged <60 and ≥60 years, respectively. Our data indicated that a complete vaccination with a booster reduced the risk of asymptomatic or mild Delta or Omicron variant COVID-19 progressing to pneumonia and, thus, reduced the pressure of severe illness on medical resources. |
format | Online Article Text |
id | pubmed-9413898 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-94138982022-08-27 Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022 Li, Juan Song, Rui Yuan, Zheng Xu, Zheng Suo, Luodan Wang, Qing Li, Yuan Gao, Yanlin Li, Xiaomei Chen, Xiaoyou Wu, Jiang Vaccines (Basel) Article This real-world study explores the effect of coronavirus disease 2019 (COVID-19) inactivated vaccines on the prevention of asymptomatic or mild Delta or Omicron variant infections progressing to pneumonia. Association between severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pneumonia cases and vaccination was measured with a multivariable logistic regression, stratified by genotype and age groups. We recruited 265 cases (111 (41.9%) infected with Delta and 154 (58.1%) with Omicron variants). There were 22 asymptomatic infected individuals, 156 mild cases without pneumonia, and 87 moderate cases with pneumonia. There was a markedly increased risk of progression to pneumonia in Delta infected cases, unvaccinated, or partially vaccinated COVID-19 patients with diabetes and those aged ≥60 years. Patients who had completed booster doses of inactivated vaccines had a reduced risk of 81.6% (95% CI: 55.6–92.4%) in progressing to pneumonia over those who were unvaccinated or partially vaccinated. The risk of progressing to pneumonia was less reduced by 88.7% (95% CI: 56.6–97%) and 73.9% (95% CI: 1.4–93.1%) among Delta and Omicron-infected patients, and was reduced by 78.5% (95% CI: 45.3–91.6%) and 94.1% (95% CI: 21.5–99.6%) among patients aged <60 and ≥60 years, respectively. Our data indicated that a complete vaccination with a booster reduced the risk of asymptomatic or mild Delta or Omicron variant COVID-19 progressing to pneumonia and, thus, reduced the pressure of severe illness on medical resources. MDPI 2022-07-29 /pmc/articles/PMC9413898/ /pubmed/36016103 http://dx.doi.org/10.3390/vaccines10081215 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Li, Juan Song, Rui Yuan, Zheng Xu, Zheng Suo, Luodan Wang, Qing Li, Yuan Gao, Yanlin Li, Xiaomei Chen, Xiaoyou Wu, Jiang Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022 |
title | Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022 |
title_full | Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022 |
title_fullStr | Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022 |
title_full_unstemmed | Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022 |
title_short | Protective Effect of Inactivated COVID-19 Vaccines against Progression of SARS-CoV-2 Omicron and Delta Variant Infections to Pneumonia in Beijing, China, in 2022 |
title_sort | protective effect of inactivated covid-19 vaccines against progression of sars-cov-2 omicron and delta variant infections to pneumonia in beijing, china, in 2022 |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9413898/ https://www.ncbi.nlm.nih.gov/pubmed/36016103 http://dx.doi.org/10.3390/vaccines10081215 |
work_keys_str_mv | AT lijuan protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 AT songrui protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 AT yuanzheng protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 AT xuzheng protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 AT suoluodan protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 AT wangqing protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 AT liyuan protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 AT gaoyanlin protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 AT lixiaomei protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 AT chenxiaoyou protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 AT wujiang protectiveeffectofinactivatedcovid19vaccinesagainstprogressionofsarscov2omicronanddeltavariantinfectionstopneumoniainbeijingchinain2022 |